Jeffrey G. Proctor, M.D., is Chairman of Urigen's Scientific Advisory Board. Dr. Proctor is Director of Interstitial Cystitis at GA Urology, PA in Riverdale, Georgia where he has practiced since November 1997. Dr. Proctor completed his Doctor of Medicine and his Residency in Urology at New York Medical College, Westchester County Medical Center, Valhalla, New York. Dr. Proctor's areas of urologic expertise are Interstitial Cystitis, Overactive Bladder, and Interstim Therapy. Dr. Proctor served as Lieutenant Commander in the Navy at the Naval Hospital Pensacola, where he served as Chief of Urology. Dr. Proctor is board-certified by the American Board of Urology and is a member of American Urological Association, Southeastern Section American Urological Association, Society of Infections and Inflammation in Urology and GAG Society.
C. Lowell Parsons, M.D., a director and Chief Medical Officer of Urigen, is a leader in medical research into the causes and treatment of interstitial cystitis, which is a painful bladder syndrome with typical cystoscopic and/or histological features in the absence of infection or other pathology, and has published over 200 scientific articles and book chapters in this area describing his work. Dr. Parsons received his M.D. degree from the Yale University School of Medicine in New Haven, CT, in 1970. After completing his medical internship at Yale in 1971, Dr. Parsons spent two years as a staff associate in the Laboratory of Microbiology at the National Institutes of Health in Bethesda, Maryland. He then completed his urology residency training at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, in 1977. Dr. Parsons joined the Division of Urology faculty at the University of California, San Diego, or UCSD, in 1977 as assistant professor. He served as Chief of Urology at the UCSD-affiliated Veterans Affairs Medical Center in La Jolla from 1977 to 1985. Since 1988, he has been Professor of Surgery/Urology.
William K. Schmidt, Ph.D., is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs, and simultaneously part-time VP of Clinical Development at CrystalGenomics, Inc. (Seoul, South Korea), and its US subsidiary, CG Pharmaceuticals. Dr. Schmidt is also part-time VP of Regulatory and Clinical for Arcion Therapeutics in Baltimore, MD. Dr. Schmidt was previously Senior VP of Development at Limerick BioPharma, VP, Clinical Research, for Renovis, Inc., and VP, Scientific Affairs, at Adolor Corporation. At Adolor, Dr. Schmidt was a key member of the team leading to the clinical development, NDA filing, and FDA approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist. Dr. Schmidt continues as a Scientific Advisory Consultant to Adolor and to other companies throughout North America, Europe, Asia, Latin America, and Australia. Dr. Schmidt currently sits on the Scientific or Medical Advisory Boards of one academic laboratory and 3 biotech companies worldwide.
Dr. Schmidt is the Parliamentarian and a Past-President of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. He has over 25 years of pharmaceutical industry experience with a special emphasis on the discovery and development of novel analgesic and narcotic antagonist drugs. He is the co-editor of “Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery” (Marcel Dekker, 2003; 2nd edition in preparation). Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco. Following his postdoctoral fellowship at Boston University School of Medicine, Dr. Schmidt joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™.